Galectin Therapeutics (GALT) Treasury Shares (2010 - 2026)

Galectin Therapeutics' Treasury Shares history runs 17 years deep, the most recent figure standing at $4.2 million for Q1 2026.

• On a quarterly basis, Treasury Shares fell 56.52% year-over-year to $4.2 million in Q1 2026; TTM through Mar 2026 was $4.2 million, a 56.52% decrease from a year earlier, with the FY2025 full-year figure at $4.2 million, down 56.52% from the prior year.
• Treasury Shares held at $4.2 million in Q1 2026 per GALT's latest filing, from $4.2 million in the prior quarter.
• Across five years, Treasury Shares topped out at $12.0 million in Q2 2023 and bottomed at $176.0 in Q4 2022.
• The 5-year median for Treasury Shares is $9.6 million (2025), against an average of $8.0 million.
• Biggest YoY gain for Treasury Shares was 6169197.73% in 2022; the steepest drop was 100.0% in 2022.
• Year by year, Treasury Shares stood at $176.0 in 2022, then soared by 5259271.02% to $9.3 million in 2023, then sank by 100.0% to $176.0 in 2024, then jumped by 2370436.36% to $4.2 million in 2025, then changed by 0.0% to $4.2 million in 2026.
• Per Business Quant, the three latest GALT Treasury Shares figures stand at $4.2 million (Q1 2026), $4.2 million (Q4 2025), and $4.0 million (Q3 2025).